ASCO has held true to this vision. Over five decades, ASCO and its members have established and advanced the field of modern clinical oncology. In many ways, the story of ASCO is the story of progress against cancer. As ASCO grew from its original seven members to nearly 45,000 today, national funding for cancer research increased from less than $200 million to more than $5 billion annually. The number of drugs available to treat cancer grew from just a handful to more than 170. And, most importantly, patients are living longer and better lives. ASCO’s members, together with patients with cancer, patient advocates, and the policymakers, government agencies, and philanthropic organizations like the Conquer Cancer Foundation that have invested in vital research, have enabled and delivered these remarkable advances.

Update:

As public health safety measures related to COVID-19 extend, the ASCO Board has concluded that the Annual Meeting, scheduled for May 29-June 2 in Chicago, cannot occur in person as planned.  

https://meetings.asco.org/am/asco-statement-novel-coronavirus-covid-19